- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring Novel Options for the Management of Uncomplicated UTIs
Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE 1 and REASSURE trial findings whereas gepotidacin works through a novel mechanism as a triazaacenaphthylene bacterial topoisomerase inhibitor targeting resistant pathogens via unique DNA gyrase and topoisomerase IV binding sites, with EAGLE trial findings demonstrating noninferiority to nitrofurantoin with approximately 90% cure rates.
EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)
EP: 2.Trends in Uncomplicated UTIs
EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs
EP: 4.Examining Uncomplicated UTI Recurrence
EP: 5.Role of Patients’ Education in Uncomplicated UTIs
EP: 6.Patient Burden Associated With Uncomplicated UTIs
EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
EP: 8.Examining the Need for Updated Guidelines for Uncomplicated UTIs
EP: 9.Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
EP: 10.Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
EP: 11.Recurrence Rates in Uncomplicated UTIs
EP: 12.Economic Burden Associated With Uncomplicated UTIs
EP: 13.Important Updates in the Management of Uncomplicated UTIs
EP: 14.Exploring Novel Options for the Management of Uncomplicated UTIs
EP: 15.Comparing Newer With Traditional Agents in Uncomplicated UTIs
EP: 16.Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
EP: 17.Final Panel Thoughts on Uncomplicated UTI Management
Video content above is prompted by the following:
- In October 2024, sulopenem etzadroxil/probenecid received FDA approval for uncomplicated urinary tract infection (UTI) based on the SURE 1 and REASSURE data. What is the mechanism of action of this therapy, and what are some key efficacy and safety points to be shared?
- Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action different from the other 2 newly approved therapies?
What are some key points to share regarding the methodology and outcomes of the EAGLE trials?
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
